EUVIMEDEUVIMED entdecken
Crossref

Diagnostic impact of RNA-based next-generation sequencing fusion panel for solid tumors: A single-institution experience

Fei Fei iD, Christian A Kunder iD, Chandler Ho, James L Zehnder, Gianna Tomasello, Eula Fung, Carlos J Suarez

American Journal of Clinical Pathology · 2024

DOI: 10.1093/ajcp/aqad148 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2024. Verfasst von Fei Fei und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Stanford University School of Medicine, Stanford, CA, US. Hauptthemen laut MEDLINE: RNA, Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Gene rearrangements frequently act as oncogenic driver mutations and determine the onset and progression of cancer. RNA-based next-generation sequencing (NGS) is being used with increasing frequency for solid tumors. The purpose of our study is to investigate the feasibility and utility of an RNA-based NGS fusion panel for solid tumors.

Methods

We conducted a retrospective, single-institution review of fusion panels requested between May 2022 and March 2023. Demographic, clinical, pathologic, and molecular findings of the patients were reviewed. The utility of the RNA-based NGS fusion panel for the pathologic diagnosis of solid tumors was assessed.

Results

Our study included 345 cases, and a fusion event was identified in 24.3% (78/321) of cases. Among the 110 cases submitted for diagnostic purposes, a fusion event was detected in 42.7% (47/110) of cases. The results led to refinement or clarification of the initial diagnosis in 31.9% (15/47) of cases and agreement or support for the initial diagnosis in 59.6% (28/47) of cases. Furthermore, our study indicated that the overall cellularity (tumor and normal tissue) of the tested specimen influences the success of the testing process.

Conclusions

In summary, this study demonstrated the feasibility and utility of an RNA-based NGS fusion panel for a wide variety of solid tumors in the appropriate clinicopathologic context. These findings warrant further validation in larger studies involving multiple institutional patient cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNANeoplasmsHumansRetrospective StudiesGene RearrangementHigh-Throughput Nucleotide Sequencing

Stichwörter der Autor:innen

RNA-based next-generation sequencingfusionsolid tumor

Substanzen

RNA

Autor:innen und Institutionen

  • Department of Pathology, Stanford University School of Medicine, Stanford, CA, US.
  • Department of Pathology, City of Hope Medical Center, Duarte, CA, US.

ORCID-Profile: Fei Fei, Christian A Kunder

Zitieren

APA

Fei, F., Kunder, C. A., Ho, C., Zehnder, J. L., Tomasello, G., Fung, E., & Suarez, C. J. (2024). Diagnostic impact of RNA-based next-generation sequencing fusion panel for solid tumors: A single-institution experience. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqad148

Vancouver

Fei F, Kunder CA, Ho C, Zehnder JL, Tomasello G, Fung E, et al. Diagnostic impact of RNA-based next-generation sequencing fusion panel for solid tumors: A single-institution experience. American Journal of Clinical Pathology. 2024. doi:10.1093/ajcp/aqad148

BibTeX
@article{Fei2024,
  author = {Fei, Fei and Kunder, Christian A and Ho, Chandler and Zehnder, James L and Tomasello, Gianna and Fung, Eula and Suarez, Carlos J},
  title = {Diagnostic impact of RNA-based next-generation sequencing fusion panel for solid tumors: A single-institution experience},
  journal = {American Journal of Clinical Pathology},
  year = {2024},
  doi = {10.1093/ajcp/aqad148}
}
Kostenlos starten →